What is Interscope?
Interscope Med is dedicated to the innovation and development of the EndoRotor®, a cutting-edge interventional device engineered for endoscopic procedures. This sophisticated technology is designed to overcome critical challenges in gastroenterology, including endoscopic necrosectomy, the management of incomplete resections, and the treatment of scarred lesions post-endoscopic mucosal resection. The EndoRotor® aims to augment the capabilities of current gastrointestinal tools, providing medical professionals, particularly gastroenterologists, with enhanced therapeutic options. The company's commitment to advancing therapeutic endoscopy is further demonstrated through its ongoing clinical studies and focus on novel solutions.
How much funding has Interscope raised?
Interscope has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Interscope
PPP
Public-Private Partnership
What's next for Interscope?
With a substantial total funding amount of $350K and a recent major strategic investment of $350K, Interscope is well-positioned for its next phase of growth. The 'large-scale late-stage funding' context suggests the company is likely scaling its operations, expanding market reach, and potentially investing further in research and development to enhance its product pipeline. This strategic capital infusion is expected to accelerate the adoption of the EndoRotor® and solidify Interscope's position as a key player in the medical device sector, particularly within the specialized field of therapeutic endoscopy.
See full Interscope company page
